Skip to main content

Drug Interactions between belinostat and Truqap

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

belinostat capivasertib

Applies to: belinostat and Truqap (capivasertib)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inhibitors of UGT1A1 may increase the plasma concentrations of belinostat, which is primarily (80% to 90%) metabolized by UGT1A1-mediated glucuronidation. Atazanavir, a UGT1A1 inhibitor, decreased the peak plasma concentration (Cmax) of belinostat by 33% but increased systemic exposure (AUC) by 1.4-fold.

MANAGEMENT: Concomitant use of belinostat with UGT1A1 inhibitors should generally be avoided. If concomitant use of a UGT1A1 inhibitor is unavoidable, the manufacturer recommends that the dosage of belinostat be decreased by 25%; 1,000 mg/m2 dose modified to 750 mg/m2, 750 mg/m2 dose modified to 562.5 mg/m2, and 500 mg/m2 dose discontinued for the duration of UGT1A1 inhibitor use and restarted at the previous dose after five half-lives of the UGT1A1 inhibitor. Patients should be monitored closely for potentially increased adverse effects of belinostat such as nausea, vomiting, diarrhea, thrombocytopenia, leukopenia (neutropenia and lymphopenia), anemia, infection, and hepatotoxicity.

Drug and food/lifestyle interactions

Major

capivasertib food/lifestyle

Applies to: Truqap (capivasertib)

Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with capivasertib as they may increase the blood levels of capivasertib. This may increase the risk of side effects such as high blood sugar levels, diarrhea, skin reactions, nausea, vomiting, tiredness, and changes in certain blood tests. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer